CN111077235B - Method for determining 2- [ (2-methyl-5-bromophenyl) methyl ] -5- (4-fluorophenyl) thiophene impurity - Google Patents
Method for determining 2- [ (2-methyl-5-bromophenyl) methyl ] -5- (4-fluorophenyl) thiophene impurity Download PDFInfo
- Publication number
- CN111077235B CN111077235B CN201811224636.9A CN201811224636A CN111077235B CN 111077235 B CN111077235 B CN 111077235B CN 201811224636 A CN201811224636 A CN 201811224636A CN 111077235 B CN111077235 B CN 111077235B
- Authority
- CN
- China
- Prior art keywords
- methyl
- solution
- diluent
- thiophene
- bromophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012535 impurity Substances 0.000 title claims abstract description 51
- 238000000034 method Methods 0.000 title claims abstract description 27
- VLRIERSBZHUCOW-UHFFFAOYSA-N 2-[(5-bromo-2-methylphenyl)methyl]-5-(4-fluorophenyl)thiophene Chemical compound CC1=CC=C(Br)C=C1CC1=CC=C(C=2C=CC(F)=CC=2)S1 VLRIERSBZHUCOW-UHFFFAOYSA-N 0.000 title claims abstract description 10
- 238000004811 liquid chromatography Methods 0.000 claims abstract description 6
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 claims abstract description 4
- 239000008055 phosphate buffer solution Substances 0.000 claims abstract 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 54
- 239000003085 diluting agent Substances 0.000 claims description 29
- 239000000243 solution Substances 0.000 claims description 23
- 239000000523 sample Substances 0.000 claims description 19
- 239000013558 reference substance Substances 0.000 claims description 16
- 239000011550 stock solution Substances 0.000 claims description 16
- 238000007865 diluting Methods 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 239000012488 sample solution Substances 0.000 claims description 13
- 238000005303 weighing Methods 0.000 claims description 11
- 239000007853 buffer solution Substances 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 8
- -1 2- [ (2-methyl-5-bromophenyl) methyl ] -5- (2-fluorophenyl) thiophene Chemical compound 0.000 claims description 7
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 6
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 6
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 5
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229930192474 thiophene Natural products 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims 1
- 229960001713 canagliflozin Drugs 0.000 abstract description 24
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 abstract description 24
- 239000007858 starting material Substances 0.000 abstract description 23
- 238000006115 defluorination reaction Methods 0.000 abstract description 13
- 229910052731 fluorine Inorganic materials 0.000 abstract description 13
- 239000011737 fluorine Substances 0.000 abstract description 13
- 230000005526 G1 to G0 transition Effects 0.000 abstract 1
- ULJWXUZHULWYTB-UHFFFAOYSA-M sodium;acetonitrile;dihydrogen phosphate Chemical compound [Na+].CC#N.OP(O)([O-])=O ULJWXUZHULWYTB-UHFFFAOYSA-M 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000009210 therapy by ultrasound Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000001612 separation test Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- FQZFOBAWUGAYRU-UHFFFAOYSA-N 2-[(5-bromo-2-methylphenyl)methyl]-5-phenylthiophene Chemical compound CC1=CC=C(Br)C=C1CC1=CC=C(C=2C=CC=CC=2)S1 FQZFOBAWUGAYRU-UHFFFAOYSA-N 0.000 description 1
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 description 1
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 description 1
- 102100020888 Sodium/glucose cotransporter 2 Human genes 0.000 description 1
- 101710103228 Sodium/glucose cotransporter 2 Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical group [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N2030/065—Preparation using different phases to separate parts of sample
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Abstract
The invention provides a method for determining defluorination (BMPT) and o-fluorine (BMOF) impurities of a canagliflozin starting material 2- [ (2-methyl-5-bromophenyl) methyl ] -5- (4-fluorophenyl) thiophene (BMFT). According to the method, a liquid chromatography method is adopted, a pentafluoro-phenyl chromatographic column is used as a stationary phase, acetonitrile-sodium dihydrogen phosphate buffer solution is used as a mobile phase, a starting material BMFT, impurities BMPT and BMOF can be effectively separated, the peak shape of each impurity is good, the column efficiency is high, the specificity is good, and the quality of a canagliflozin starting material (BMFT) is well controlled.
Description
Technical Field
The invention belongs to the field of analytical chemistry, and particularly relates to a method for preparing 2- [ (2-methyl-5-bromophenyl) methyl ] -5- (4-fluorophenyl) thiophene and impurities thereof.
Background
2- [ (2-methyl-5-bromophenyl) methyl group]-5- (4-fluorophenyl) thiophene (hereinafter referred to as "BMFT"), which is a key starting material for the production of canagliflozin, a novel drug for diabetes that improves glycemic control, developed by the young company under the flag of strong united states, is marketed as an inhibitor of sodium-glucose cotransporter 2 (SGLT 2), and is used in combination with dietary control and exercise to improve glycemic control in adult patients with type 2 diabetes. Control of BMPT with two important impurities in BMFT and BMOF with o-fluorine is important, and BMFT has a molecular formula of C 18 H 14 BrFS, a compound of formula (I) having the chemical formula: 2- [ (2-methyl-5-bromophenyl) methyl group]-5- (4-fluorophenyl) thiophene
。
During the synthesis of BMFT, impurities of 2- (5-bromo-2-methylbenzyl) -5-phenylthiophene (BMPT for short) and 2- (5-bromo-2-methylphenyl) -5- (2-fluorophenyl) thiophene (BMOF for short) are generated, wherein the BMPT has a molecular formula of C 18 H 15 BrS the BMOF has the formula C 18 H 14 BrFS of the chemical structural formula
。
Using conventional general C 18 And conventional mobile phase HPLC, it is difficult to separate these two impurities (BMOF, BMPT) from BMFT effectively, peak shape is poor, column efficiency is low, and they are completely coincident.
In order to effectively control the quality of the starting material BMFT of the canagliflozin and ensure the quality of finished canagliflozin, it is necessary to research a measuring method capable of effectively separating the canagliflozin starting material (BMFT) from the two impurities, so that the effective control of the impurities BMOF and BMPT in the canagliflozin starting material (BMFT) is realized, and the method has important significance for the quality control of the canagliflozin bulk drug and the preparation.
Disclosure of Invention
The invention aims to provide a method for separating and measuring 2- [ (2-methyl-5-bromophenyl) methyl ] -5- (4-fluorophenyl) thiophene and impurities thereof, which can effectively separate and measure 2- [ (2-methyl-5-bromophenyl) methyl ] -5- (4-fluorophenyl) thiophene (BMFT) and impurities thereof (BMPT, BMOF), realize quality control of a canagliflozin starting material and ensure quality of a canagliflozin finished product.
In one embodiment, a method of the present invention for the isolation of 2- [ (2-methyl-5-bromophenyl) methyl ] -5- (4-fluorophenyl) thiophene and its impurities, which impurity compounds are 2- [ (2-methyl-5-bromophenyl) methyl ] -5- (2-fluorophenyl) thiophene (BMOF) and 2- [ (2-methyl-5-bromophenyl) methyl ] -5-phenyl) thiophene (BMPT), is a liquid chromatography method comprising: 1) the column is a pentafluoro-phenyl column, preferably a PFP 4.6x250 mm,5 μm column, 2) the mobile phase consists of acetonitrile-buffer, wherein the buffer is sodium dihydrogen phosphate, 3) the volume ratio of acetonitrile to buffer in the mobile phase is: acetonitrile is 50% -60%, and buffer solution is 40% -50%.
Preferably, in the above method of the present invention, the pH value of the buffer solution ranges from 2.0 to 8.0, preferably 2.5; the volume ratio of acetonitrile to buffer in the mobile phase acetonitrile-buffer is 55:45.
The above-described method for separating and measuring 2- [ (2-methyl-5-bromophenyl) methyl ] -5- (4-fluorophenyl) thiophene and its impurities according to the present invention further comprises the steps of:
a) Control solution: accurately weighing 15mg of each of the impurity compounds BMPT and BMOF reference substances, respectively placing into 100ml volumetric flasks, dissolving and diluting to scale with a diluent, shaking uniformly, taking the mixture as a reference substance stock solution, accurately weighing 1ml of the reference substance stock solution, placing into the same 100ml volumetric flask, diluting to scale with the diluent, shaking uniformly, and taking the mixture as a mixed reference substance solution, wherein the sample solution is as follows: taking BMFT 25mg, placing in a bottle with 25ml capacity, dissolving with a diluent, diluting to a scale, and shaking uniformly to obtain a sample solution;
b) Setting the flow rate of the mobile phase to be 1.0-1.5 ml/min, the pH value range of the buffer solution in the mobile phase to be 2.0-8.0, the detection wavelength to be 210-290 nm, the column temperature of the chromatographic column to be 20-35 ℃ and the sample injection amount to be 5-100 mu L;
c) Taking the same volume of the mixed control solution and the sample solution in the step a), respectively injecting the mixed control solution and the sample solution into a liquid chromatograph, recording a chromatogram, and completing the separation and the determination of the canagliflozin starting material BMFT and impurities BMPT and BMOF thereof.
In the above method of the present invention, the diluent in step a) is acetonitrile, the flow rate of the mobile phase in step b) is 1.5ml/min, the detection wavelength is 210nm, the pH value of the buffer solution in the mobile phase is 2.5, the column temperature of the chromatographic column in step b) is 30 ℃, and the sample injection amount is 20. Mu.L.
In a specific embodiment, the method of the invention, the specific chromatographic conditions are preferably as follows:
instrument: agilent 1260 high performance liquid chromatograph
Chromatographic column: PFP, 4.6X105 mm,5 μm;
sample injection amount: 20 μl;
flow rate: 1.5ml/min;
column temperature: 30 ℃;
detection wavelength: 210nm;
a diluent: acetonitrile
Mobile phase: sodium dihydrogen phosphate solution (pH value is adjusted to 2.5 by phosphoric acid) with the concentration of 0.002 mol/L: acetonitrile (45:55V/V).
The method has the beneficial effects that: the method can effectively separate defluorination (BMPT) and o-fluorine (BMOF) impurities of the canagliflozin starting material (BMFT), can accurately measure the defluorination (BMPT) and the o-fluorine (BMOF) impurities of the canagliflozin starting material (BMFT), has symmetrical peak shape and higher column efficiency, and can accurately control the quality of the canagliflozin starting material (BMFT), and the defluorination (BMPT) and the o-fluorine (BMOF) impurities of the canagliflozin starting material (BMFT) can be simply, quickly and accurately separated and detected.
Particularly, the method adopts the pentafluoro-phenyl chromatographic column, and the chromatographic column has low cost, can effectively separate and detect defluorinated (BMPT) and o-fluoro (BMOF) impurities of the canagliflozin starting material (BMFT), and can also reach corresponding requirements on sensitivity. Acetonitrile is selected as a diluent to dissolve the sample, so that the sample is prevented from being separated out in a mobile phase, impurities and the sample can be fully dissolved, and larger solvent peak interference is avoided; the column temperature is 30 ℃, the durability of the column temperature is good, the peak shape is good, and the separation degree can be optimized. The mobile phase was adjusted to pH 2.5 with phosphoric acid in a 0.002mol/L sodium dihydrogen phosphate solution: acetonitrile (45:55) can effectively separate defluorination (BMPT) and ortho-fluorine (BMOF) impurities of a canagliflozin starting material (BMFT), and meanwhile, the working efficiency is improved. The invention solves the problem that defluorination (BMPT) and o-fluorine (BMOF) impurities of the starting material (BMFT) for separating and measuring the canagliflozin are difficult to separate, thereby ensuring the quality controllability of the canagliflozin starting material (BMFT).
Drawings
FIG. 1 is a liquid chromatogram of a blank solvent;
FIG. 2 impurity defluorination (BMPT), ortho-fluorine (BMOF) localization liquid chromatograms (2-1, 2-2);
FIG. 3 is a liquid chromatogram of impurity defluorination (BMPT) and ortho-fluoro (BMOF) control mixtures;
FIG. 4 liquid chromatogram of a canagliflozin starting material (BMFT) mixed with defluorinated (BMPT), ortho-fluoro (BMOF);
FIG. 5 is a liquid chromatogram of a sample solution of canagliflozin starting material (BMFT);
Detailed Description
The following examples serve to further illustrate and understand the spirit of the invention but do not limit the scope of the invention in any way.
Example 1
Instrument and conditions
An Agilent 1260 liquid chromatograph and Instrument workstation in the united states; automatic sample injection;
instrument: agilent 1260 high performance liquid chromatograph
Chromatographic column: PFP, 4.6X105 mm,5 μm;
sample injection amount: 20 μl;
flow rate: 1.5ml/min;
column temperature: 30 ℃;
detection wavelength: 210nm;
a diluent: acetonitrile
Mobile phase: sodium dihydrogen phosphate solution (pH value is adjusted to 2.5 by phosphoric acid) with the concentration of 0.002 mol/L: acetonitrile (45:55).
The experimental steps are as follows:
preparing an impurity stock solution: respectively precisely weighing about 15mg of reference substances of BMOF and BMPT, respectively placing into 100ml volumetric flasks, adding a proper amount of diluent, performing ultrasonic treatment to dissolve, diluting with the diluent to scale, shaking uniformly to obtain impurity stock solution I, precisely weighing 5ml of reference substances, placing into 50ml volumetric flasks, diluting with the diluent to scale, and shaking uniformly to obtain impurity stock solution II.
Preparing a positioning solution: respectively placing 1ml of the above impurity stock solution into different 100ml volumetric flasks, diluting with diluent to scale, and shaking to obtain positioning solutions (see figures 2-1 and 2-2).
Preparing a mixed reference substance solution: and (3) putting 5ml of each impurity stock solution II into the same 50ml volumetric flask, diluting with a diluent to a scale, and shaking uniformly to obtain the final product (see figure 3).
Preparing a sample and mixed impurity reference substance solution: taking 25mg of BMFT sample, precisely weighing, placing into a 25ml volumetric flask, adding 2.5ml of each impurity stock solution II and a proper amount of diluent, performing ultrasonic treatment to dissolve, diluting to scale with the diluent, and shaking uniformly to obtain the final product (see figure 4).
Respectively taking blank solution (diluent), positioning solution, mixed control solution and impurity control solution of sample, performing liquid chromatography according to the above chromatographic conditions, and recording chromatogram; the results are shown in fig. 1, fig. 2, fig. 3 and fig. 4.
The retention time 28.939min in FIG. 2 (2-1) is impurity defluorination (BMPT) and the retention time 30.529min in FIG. 2 (2-2) is chromatographic peak of impurity o-fluorine (BMOF),
fig. 1 shows that the solvent does not interfere with the assay,
FIG. 4 shows that the method can effectively detect impurity defluorination (BMPT) and o-fluorine (BMOF) of the canagliflozin starting material (BMFT), the separation degree is more than 1.5, and the method can be used for measuring the impurity defluorination (BMPT) and the o-fluorine (BMOF) of the canagliflozin starting material (BMFT).
Example 2
Instrument and conditions (same example 1)
An Agilent 1260 liquid chromatograph and Instrument workstation in the united states; automatic sample injection;
instrument: agilent 1260 high performance liquid chromatograph
Chromatographic column: PFP, 4.6X105 mm,5 μm;
sample injection amount: 20 μl;
flow rate: 1.5ml/min;
column temperature: 30 ℃;
detection wavelength: 210nm;
a diluent: acetonitrile
Mobile phase: sodium dihydrogen phosphate solution (pH value is adjusted to 2.5 by phosphoric acid) with the concentration of 0.002 mol/L: acetonitrile (45:55).
The experimental steps are as follows:
the defluorinated (BMPT), ortho-fluoro (BMOF) impurities of the canagliflozin starting material (BMFT) were determined by liquid chromatography.
Taking the BMFT of about 25mg, precisely weighing, placing into a 25ml measuring flask, dissolving with a diluent, diluting to a scale, and shaking uniformly to obtain a sample solution. Preparing a reference substance solution: respectively taking 5ml of the impurity stock solution II, placing into a 50ml volumetric flask, adding diluent to dilute to scale, shaking uniformly, and taking as reference substance solution. The liquid chromatography was performed according to the chromatographic conditions of example 1, and the content of the sample solution was calculated according to the external standard method, except for the solvent peak and the system peak, if there was a chromatographic peak at the position corresponding to the defluorination (BMPT) and the ortho-fluorine (BMOF) impurities, and if there was no chromatographic peak at the position corresponding to the defluorination (BMPT) and the ortho-fluorine (BMOF) impurities, the content was not calculated. The results are shown in FIG. 5.
Comparison experiment:
instrument and conditions
An Agilent 1260 liquid chromatograph and Instrument workstation in the united states; automatic sample injection;
instrument: agilent 1260 high performance liquid chromatograph
Column temperature: 30 ℃;
detection wavelength: 210nm;
a diluent: acetonitrile
Sample injection amount: 20 μl;
flow rate: 1.5ml/min
The steps are as follows:
preparing an impurity stock solution: respectively precisely weighing about 15mg of each of the BMOF and BMPT reference substances, respectively placing into 100ml volumetric flasks, adding a proper amount of diluent, performing ultrasonic treatment to dissolve, diluting with the diluent to a scale, shaking uniformly to obtain an impurity stock solution I, precisely weighing 5ml of the impurity stock solution I, placing into 50ml volumetric flasks, diluting with the diluent to the scale, and shaking uniformly to obtain an impurity stock solution II.
Preparing a mixed reference substance solution: and (3) putting 5ml of each impurity stock solution II into the same 50ml volumetric flask, adding a diluent to dilute to a scale, and shaking uniformly to obtain the product.
Test solution: adding mixed reference substance solution into sample, precisely weighing 25mg of the sample, placing into 25ml volumetric flask, adding 2.5ml of each impurity stock solution II and appropriate amount of diluent, performing ultrasonic treatment to dissolve, diluting to scale with diluent, and shaking.
Taking 20 μl of the sample solution, and testing the sample solution according to different chromatographic columns, buffer solutions and mobile phase proportion conditions in the following table.
TABLE 1 test conditions and test results for test solutions
The experimental results in table 1 show that the technical scheme of the invention can obtain good separation test effect, and well control the quality of the initial materials, thereby ensuring the quality of the finished products. The buffer solution of the C18 chromatographic column and the mobile phase is monopotassium phosphate or the proportion thereof is changed, so that good separation test effect is difficult to obtain, and the quality of the starting materials is not controlled.
Simple substitutions or modifications of the present invention without changing the spirit of the invention also fall within the scope of the invention.
Claims (6)
1. A method for the separation and determination of 2- [ (2-methyl-5-bromophenyl) methyl ] -5- (4-fluorophenyl) thiophene and its impurities, 2- [ (2-methyl-5-bromophenyl) methyl ] -5- (2-fluorophenyl) thiophene and 2- [ (2-methyl-5-bromophenyl) methyl ] -5-phenyl) thiophene, the method being liquid chromatography comprising: 1) the chromatographic column is a pentafluoro-phenyl chromatographic column, 2) the mobile phase consists of acetonitrile-buffer solution, wherein the buffer solution is sodium dihydrogen phosphate buffer solution, the pH value is 2.5,3), and the volume ratio of acetonitrile to the buffer solution in the mobile phase is 55:45.
2. the method of claim 1, comprising the steps of:
a) Control solution: accurately weighing 15mg of each impurity compound reference substance, respectively placing into 100ml volumetric flasks, dissolving with diluent, diluting to scale, shaking up to obtain reference substance stock solution, accurately weighing 1ml, placing into the same 100ml volumetric flask, diluting with diluent to scale, shaking up to obtain mixed reference substance solution, and testing sample solution: taking 25mg of 2- [ (2-methyl-5-bromophenyl) methyl ] -5- (4-fluorophenyl) thiophene, placing in a bottle with a capacity of 25ml, dissolving with a diluent, diluting to a scale, and shaking uniformly to obtain a sample solution;
b) Setting the flow rate of the mobile phase to be 1.0-1.5 ml/min, the pH value of the buffer solution in the mobile phase to be 2.5, the detection wavelength to be 210-290 nm, the column temperature of the chromatographic column to be 20-35 ℃ and the sample injection amount to be 5-100 mu L;
c) Taking the same volume of the mixed control solution and the sample solution in the step a), respectively injecting the mixed control solution and the sample solution into a liquid chromatograph, recording a chromatogram, and completing separation and measurement.
3. The process of claim 2, wherein the diluent of step a) is acetonitrile.
4. The method according to claim 2, wherein the mobile phase in step b) has a flow rate of 1.5ml/min and the detection wavelength is 210nm.
5. The method of claim 2, wherein the column temperature of the chromatographic column in step b) is 30 ℃.
6. The method of claim 2, wherein the sample size in step b) is 20 μl.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811224636.9A CN111077235B (en) | 2018-10-19 | 2018-10-19 | Method for determining 2- [ (2-methyl-5-bromophenyl) methyl ] -5- (4-fluorophenyl) thiophene impurity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811224636.9A CN111077235B (en) | 2018-10-19 | 2018-10-19 | Method for determining 2- [ (2-methyl-5-bromophenyl) methyl ] -5- (4-fluorophenyl) thiophene impurity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111077235A CN111077235A (en) | 2020-04-28 |
| CN111077235B true CN111077235B (en) | 2023-09-08 |
Family
ID=70308303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811224636.9A Active CN111077235B (en) | 2018-10-19 | 2018-10-19 | Method for determining 2- [ (2-methyl-5-bromophenyl) methyl ] -5- (4-fluorophenyl) thiophene impurity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111077235B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112730702A (en) * | 2020-12-30 | 2021-04-30 | 南京百泽医药科技有限公司 | Method for determining related substances of 6-acetoxyl-7-methoxy-3H-quinazoline-4-one |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016016852A1 (en) * | 2014-07-31 | 2016-02-04 | Sun Pharmaceutical Industries Limited | Process for the purification of canagliflozin |
| CN105319294A (en) * | 2014-06-20 | 2016-02-10 | 重庆医药工业研究院有限责任公司 | Method for separating and testing canagliflozin and matter related to same |
| CN108530434A (en) * | 2017-03-03 | 2018-09-14 | 重庆医药工业研究院有限责任公司 | Impurity compound of canagliflozin and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2459220T1 (en) * | 2009-07-31 | 2020-12-31 | Ascendis Pharma A/S | Biodegradable polyethylene glycol based water-insoluble hydrogels |
| US9695159B2 (en) * | 2014-05-27 | 2017-07-04 | Glenmark Pharmaceuticals Limited | Process for preparation of canagliflozin |
-
2018
- 2018-10-19 CN CN201811224636.9A patent/CN111077235B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105319294A (en) * | 2014-06-20 | 2016-02-10 | 重庆医药工业研究院有限责任公司 | Method for separating and testing canagliflozin and matter related to same |
| WO2016016852A1 (en) * | 2014-07-31 | 2016-02-04 | Sun Pharmaceutical Industries Limited | Process for the purification of canagliflozin |
| CN108530434A (en) * | 2017-03-03 | 2018-09-14 | 重庆医药工业研究院有限责任公司 | Impurity compound of canagliflozin and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 卡格列净关键中间体合成研究;钟铮 等;《河南科学》;20160831;第1241-1244页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111077235A (en) | 2020-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105738489B (en) | method for determining rivaroxaban and impurities thereof by adopting liquid chromatography | |
| CN110501446B (en) | Analysis method of oxa-goril sodium raw material and synthetic intermediate thereof | |
| CN105588886B (en) | method for determining impurities in apremilast and its preparation by liquid chromatography | |
| CN104965041A (en) | High performance liquid chromatography detection method for parecoxib sodium isomer | |
| CN113049699A (en) | Method for detecting biphenyl anhydride and related substances thereof and application | |
| CN111077235B (en) | Method for determining 2- [ (2-methyl-5-bromophenyl) methyl ] -5- (4-fluorophenyl) thiophene impurity | |
| CN106706769B (en) | Separation and determination method of empagliflozin and optical isomer thereof | |
| CN107525877B (en) | Method for separating and determining brexpiprazole and impurities thereof by adopting liquid chromatography | |
| CN105987961A (en) | Detection method of levetiracetam in breast milk | |
| CN107941946A (en) | A kind of detection method of fumaric acid vonoprazan | |
| CN115586272B (en) | Method for detecting dissolution of bripiprazole preparation and application thereof | |
| CN110780005B (en) | Analysis method of Cribolol raw material and synthetic intermediate thereof | |
| CN111707765A (en) | Topiroxostat tablet detection method | |
| CN115236255B (en) | Method for detecting related substances of loxoprofen sodium | |
| CN113533539B (en) | Method for measuring related substances peculiar to Apremix | |
| CN110865130A (en) | Detection method of olopatadine hydrochloride and related substances thereof | |
| CN104965031B (en) | Content measuring method for compound ketoprofen and omeprazole sustained-release capsules | |
| CN110579541B (en) | Detection method of lansoprazole related substances | |
| CN111077234B (en) | Method for separating and measuring canagliflozin and impurities thereof by liquid chromatography | |
| CN102680622A (en) | A kind of liquid chromatography detection method of rupatadine fumarate content | |
| CN115541762B (en) | Method for detecting related substances of ritonavir starting material 02 | |
| CN118566395B (en) | Method, application and system for determining impurity content in toluene sulfonic acid Lu Meipai protuberance orally disintegrating tablet | |
| CN116297908B (en) | Analysis method of indobufen isomer impurity | |
| CN101929987B (en) | Method for measuring relevant substances of repaglinide intermediate by high performance liquid chromatography | |
| CN115856141B (en) | Method for separating and measuring tinib key intermediate and relevant impurities thereof by HPLC |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |